title: Interstitial Lung Disease Induced by Pazopanib Treatment.
abstract: Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcoma and lung metastasis presented with dyspnea and fatigue. He had mild interstitial pneumonia when pazopanib treatment was initiated. Chest computed tomography revealed progressive bilateral ground-glass opacity (GGO) and traction bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib treatment was interrupted and a steroid was administered. The symptoms and GGO were improved with treatment. Physicians should be aware of DILD due to pazopanib in patients with pre-existing interstitial lung disease.
authors.affiliation: Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
authors.forename: Shotaro
authors.initials: S
authors.lastname: Ide
authors.forename: Noriho
authors.initials: N
authors.lastname: Sakamoto
authors.forename: Shintaro
authors.initials: S
authors.lastname: Hara
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hara
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Kakugawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Yoji
authors.initials: Y
authors.lastname: Futsuki
authors.forename: Koichi
authors.initials: K
authors.lastname: Izumikawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ishimatsu
authors.forename: Katsunori
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mukae
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D044466:Asian People; D005263:Femoral Artery / Q000503:physiopathology; D006801:Humans; D007191:Indazoles; D007564:Japan; D007890:Leiomyosarcoma / Q000188:drug therapy*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D011743:Pyrimidines; D013256:Steroids; D013449:Sulfonamides; C516667:pazopanib